Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.54 |
| ▸ | RAF1 | P04049 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334161 | 0.87 | ALDH1A1 (0.47) | PARP10RAF1ALDH1A1KMT2AMEN1 | |
| SCHEMBL4369342 | 0.87 | PARP10 (0.54) | PARP10RAF1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6383415 | 0.86 | KDR (0.47) | PARP10RAF1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6273015 | 0.86 | RAF1 (0.50) | PARP10RAF1ALDH1A1KMT2ABRAF | |
| SCHEMBL29757282 | 0.86 | P2RX3 (0.53) | RAF1P2RX3 | |
| SCHEMBL23913769 | 0.86 | P2RX3 (0.53) | RAF1P2RX3 | |
| SCHEMBL257959 | 0.86 | RAF1 (0.50) | RAF1BRAFKDRP2RX3 | |
| SCHEMBL4155509 | 0.85 | PARP10 (0.51) | PARP10RAF1BRAFKDRPARP15 | |
| SCHEMBL27796745 | 0.85 | PARP10 (0.45) | PARP10RAF1ALDH1A1KMT2AMEN1 | |
| SCHEMBL177837 | 0.84 | MAOB (0.50) | PARP10RAF1ALDH1A1MAPTBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119174764-A | Application of 4- (4-aminophenoxy) pyridine carboxamide compound in preparation of antitumor drugs and pharmaceutical composition | 江西科技师范大学 | 2024-12-24 | — | — | CN | claimed |
| CN-119174764-A | Application of 4- (4-aminophenoxy) pyridine carboxamide compound in preparation of antitumor drugs and pharmaceutical composition | 江西科技师范大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-119174764-A | Application of 4- (4-aminophenoxy) pyridine carboxamide compound in preparation of antitumor drugs and pharmaceutical composition | 江西科技师范大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-119174764-A | Application of 4- (4-aminophenoxy) pyridine carboxamide compound in preparation of antitumor drugs and pharmaceutical composition | 江西科技师范大学 | 2024-12-24 | — | — | CN | disclosed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3134088-B1 | BICYLCIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-9718841-B2 | Bicyclic pyrazolone compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2387/4885RAF1 2/4885ALDH1A1 1431/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | PARP10 3150/4885RAF1 3/4885ALDH1A1 1887/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | PARP10 3977/4885RAF1 867/4885ALDH1A1 1345/4885 |
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | MET, RET, ERBB2 | PARP10 1041/4885RAF1 23/4885ALDH1A1 2892/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | PARP10 3977/4885RAF1 867/4885ALDH1A1 1345/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2488/4885RAF1 2/4885ALDH1A1 1392/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2488/4885RAF1 2/4885ALDH1A1 1392/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | PARP10 1953/4885RAF1 4/4885ALDH1A1 1474/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2488/4885RAF1 2/4885ALDH1A1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.